Chemotherapy for squamous cell carcinoma of the head and neck is palliative only in the sense that more tolerable survival is achieved in about ½ of the patients. Length of survival is not generally prolonged and long-term remissions are infrequent. This being the case, the cheapest, most easily tolerated and least complicated form of therapy should be employed. It would seem that high dose i.v. methotrexate therapy as an outpatient comes closest to achieving these ideals. Intra-arterial infusion should be reserved for patients who fail on i.v. therapy and for research protocols.